Multi-omics Profiles are Applicable to Human Diseases and Drug Development

Abstract

Traditional medicine has been a reliable source for the discovery of molecules with therapeutic activity against human diseases of clinical interest. In the past, knowledge of traditional medicine was mainly transmitted orally and in writing. Recently, the advent of “multiomics” tools (transcriptomics, metabolomics, epigenomics, proteomics, and lipidomics, among others) has increased and merged our knowledge, both traditional knowledge and that gained with these new multiomics technologies. In this way, the development of medicines with these 'multiomics technologies' has allowed pharmaceutical advances in the discovery of new drugs. In addition, 'multiomics' technologies have made it possible to uncover new biological activities of drugs that are currently used in clinical therapy. In the same way, 'multiomics' has allowed for the development of 'personalized medicine', that is, a particular and specific treatment and/or diagnosis of a patient with respect to a disease. Therefore, 'multiomics' technologies have facilitated the discovery of new clinical therapeutics for disease, as well as allowing for the diagnosis and/or treatment of diseases in an individual and personalized way.